Kodiak Sciences Inc. (NASDAQ:KOD - Get Free Report) was up 5.1% during mid-day trading on Tuesday . The company traded as high as $3.98 and last traded at $3.90. Approximately 216,909 shares changed hands during trading, a decline of 37% from the average daily volume of 345,457 shares. The stock had previously closed at $3.71.
Analyst Upgrades and Downgrades
Separately, HC Wainwright restated a "neutral" rating and set a $3.00 price objective on shares of Kodiak Sciences in a research report on Monday, March 31st.
Get Our Latest Stock Analysis on Kodiak Sciences
Kodiak Sciences Stock Performance
The company's 50 day simple moving average is $3.83 and its two-hundred day simple moving average is $4.68.
Kodiak Sciences (NASDAQ:KOD - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.20). As a group, equities analysts forecast that Kodiak Sciences Inc. will post -3.45 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in the business. US Bancorp DE raised its holdings in Kodiak Sciences by 131.7% in the first quarter. US Bancorp DE now owns 9,282 shares of the company's stock valued at $26,000 after acquiring an additional 5,276 shares in the last quarter. Vontobel Holding Ltd. acquired a new stake in Kodiak Sciences in the first quarter valued at approximately $28,000. PNC Financial Services Group Inc. raised its holdings in Kodiak Sciences by 1,501.5% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,187 shares of the company's stock valued at $32,000 after acquiring an additional 2,988 shares in the last quarter. Walleye Capital LLC acquired a new stake in Kodiak Sciences in the first quarter valued at approximately $49,000. Finally, Russell Investments Group Ltd. raised its holdings in Kodiak Sciences by 729.9% during the first quarter. Russell Investments Group Ltd. now owns 21,039 shares of the company's stock worth $59,000 after purchasing an additional 18,504 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company's stock.
Kodiak Sciences Company Profile
(
Get Free Report)
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
See Also
Before you consider Kodiak Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.
While Kodiak Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
